吉非替尼治疗晚期非小细胞肺癌合并恶性胸腔积液的疗效及其与表皮生长因子受体基因突变的关系研究

Relationship of EGFR gene mutation and clinical efficacy of patients with terminal NSCLC treated with gefitinib from Zhoushan

目的：研究吉非替尼治疗晚期非小细胞肺癌（NSCLC）合并恶性胸腔积液的疗效及其与表皮生长因子受体（EGFR）基因突变的关系。方法选取晚期 NSCLC 合并恶性胸腔积液患者45例，采用支气管镜活检收集标本，提取 DNA，检测 EGFR 基因突变情况，同时所有患者均给予吉非替尼治疗。将 EGFR 基因发生突变患者定为突变组，EGFR 基因未发生突变患者定为正常组，比较两组患者疗效。结果突变组患者13例（28．89％），CR 6例，PR 4例，客观缓解率76．92％，无进展生存期（PFS）（232．8±24．3）d；正常组患者32例（71．11％），CR 2例，PR 8例，客观缓解率31．25％，PFS（156．7±26．5）d；突变组患者客观缓解率显著高于对照组（χ2＝7．810，P ＜0．05），并且突变组 PFS 也显著高于对照组（t ＝5．665，P ＜0．05）。结论吉非替尼治疗EGFR 基因突变的晚期 NSCLC 合并恶性胸腔积液具有更好临床效果。

Objective To study the relationship of EGFR gene mutation and clinical efficacy of patients with terminal NSCLC treated with gefitinib from Zhoushan.Methods 45 patients with terminal NSCLC were divided into the mutation group and normal group according to EGFR mutation.And all patients were received gefitinib treatment. Clinical efficacy was observed.Results The objective response rate and PFS of the mutation group were 76.92%, （232.8 ±24.3）d;The objective response rate and PFS of the normal group were 31.25%,（156.7 ±26.5）d;The objective response rate of the mutation group was significantly higher than that of the normal group（χ2 =7.810,P 〈0.05）,and the PFS of the mutation group was also significantly higher than that of the normal group（t =5.665,P 〈0.05）.Conclusion EGFR gene mutation patients with terminal NSCLC treated with gefitinib has higher clinical effi-cacy.